Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Breast Neoplasms 17Ovarian Neoplasms 11Neoplasms 8Fallopian Tube Neoplasms 8Triple Negative Breast Neoplasms 7Prostatic Neoplasms 6Neoplasm Metastasis 6Pancreatic Neoplasms 4Endometrial Neoplasms 4Neuroendocrine Tumors 3Glioma 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Recurrence 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Fanconi Anemia, Complementation Group D1 2Cholangiocarcinoma 2Uveal Melanoma 1Urogenital Neoplasms 1Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1SCLC,Extensive Stage 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Platinum-sensitive Ovarian Cancer 1

Interventions

Carboplatin 5Nivolumab 4pembrolizumab 3Pemetrexed 3Ipilimumab 3fludarabine 2atezolizumab 2Cyclophosphamide 2Cisplatin 2tremelimumab 1sotorasib 1osimertinib 1olaparib 1durvalumab 1Tumor Burden 1Thoracoscopy 1Tablets 1Saline Solution 1Quality of Life 1Observation 1Magnesium Sulfate 1Injections 1Influenza Vaccines 1Histocompatibility Testing 1Gemcitabine 1Fluorodeoxyglucose F18 1Exercise Therapy 1Combined Modality Therapy 1Cell- and Tissue-Based Therapy 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Mesothelioma × olaparib × Clear all
NCT04515836 2025-05-06

Olaparib in Patients With HRD Malignant Mesothelioma

University of Chicago

Phase 2 Recruiting
56 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡